JP2014509595A5 - - Google Patents

Download PDF

Info

Publication number
JP2014509595A5
JP2014509595A5 JP2013558234A JP2013558234A JP2014509595A5 JP 2014509595 A5 JP2014509595 A5 JP 2014509595A5 JP 2013558234 A JP2013558234 A JP 2013558234A JP 2013558234 A JP2013558234 A JP 2013558234A JP 2014509595 A5 JP2014509595 A5 JP 2014509595A5
Authority
JP
Japan
Prior art keywords
cancer
seq
immunotherapeutic composition
brachyury
yeast
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2013558234A
Other languages
English (en)
Japanese (ja)
Other versions
JP6068368B2 (ja
JP2014509595A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2012/029636 external-priority patent/WO2012125998A1/en
Publication of JP2014509595A publication Critical patent/JP2014509595A/ja
Publication of JP2014509595A5 publication Critical patent/JP2014509595A5/ja
Application granted granted Critical
Publication of JP6068368B2 publication Critical patent/JP6068368B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2013558234A 2011-03-17 2012-03-19 酵母−ブラキュリ免疫治療組成物 Active JP6068368B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161453656P 2011-03-17 2011-03-17
US61/453,656 2011-03-17
PCT/US2012/029636 WO2012125998A1 (en) 2011-03-17 2012-03-19 Yeast-brachyury immunotherapeutic compositions

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2016249307A Division JP6309607B2 (ja) 2011-03-17 2016-12-22 酵母−ブラキュリ免疫治療組成物

Publications (3)

Publication Number Publication Date
JP2014509595A JP2014509595A (ja) 2014-04-21
JP2014509595A5 true JP2014509595A5 (2) 2015-04-30
JP6068368B2 JP6068368B2 (ja) 2017-01-25

Family

ID=46831122

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2013558234A Active JP6068368B2 (ja) 2011-03-17 2012-03-19 酵母−ブラキュリ免疫治療組成物
JP2016249307A Active JP6309607B2 (ja) 2011-03-17 2016-12-22 酵母−ブラキュリ免疫治療組成物
JP2018046148A Active JP6580733B2 (ja) 2011-03-17 2018-03-14 酵母−ブラキュリ免疫治療組成物
JP2019155138A Pending JP2019199484A (ja) 2011-03-17 2019-08-28 酵母−ブラキュリ免疫治療組成物

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2016249307A Active JP6309607B2 (ja) 2011-03-17 2016-12-22 酵母−ブラキュリ免疫治療組成物
JP2018046148A Active JP6580733B2 (ja) 2011-03-17 2018-03-14 酵母−ブラキュリ免疫治療組成物
JP2019155138A Pending JP2019199484A (ja) 2011-03-17 2019-08-28 酵母−ブラキュリ免疫治療組成物

Country Status (19)

Country Link
US (5) US9198941B2 (2)
EP (2) EP2685995B1 (2)
JP (4) JP6068368B2 (2)
KR (1) KR102046449B1 (2)
CN (1) CN103648513B (2)
AU (3) AU2012228937B2 (2)
BR (1) BR112013023456B1 (2)
CA (1) CA2835475C (2)
DK (1) DK2685995T3 (2)
ES (1) ES2627979T3 (2)
HK (1) HK1245649A1 (2)
HU (1) HUE033491T2 (2)
IL (1) IL228421B (2)
MX (1) MX350661B (2)
PL (1) PL2685995T3 (2)
PT (1) PT2685995T (2)
RU (2) RU2690180C2 (2)
SG (2) SG193396A1 (2)
WO (1) WO2012125998A1 (2)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2170384T3 (en) 2007-07-02 2016-07-25 Etubics Corp METHODS AND COMPOSITIONS FOR THE PRODUCTION OF AN adenovirus vector for use in higher vaccination
US9254320B2 (en) 2010-12-17 2016-02-09 Globeimmune, Inc. Compositions and methods for the treatment or prevention of human adenovirus-36 infection
JP5745102B2 (ja) 2011-02-12 2015-07-08 グローブイミューン,インコーポレイテッド 慢性b型肝炎感染症のための酵母系免疫療法組成物
MX350661B (es) 2011-03-17 2017-09-13 Us Health Composiciones inmunoterapeuticas de levadura-brachyuri.
CN103732250A (zh) 2011-06-14 2014-04-16 全球免疫股份有限公司 基于酵母的治疗或预防丁型肝炎病毒感染的组合物和方法
SG10201607663YA (en) 2011-08-17 2016-11-29 Globeimmune Inc Yeast-muc1 immunotherapeutic compositions and uses thereof
MX365418B (es) 2012-06-26 2019-06-03 Biodesix Inc Metodo por espectros de masa para la seleccion y descarte de pacientes de cancer para el tratamiento con terapias generadoras de respuestas inmunitarias.
US9605276B2 (en) 2012-08-24 2017-03-28 Etubics Corporation Replication defective adenovirus vector in vaccination
WO2014043518A1 (en) 2012-09-14 2014-03-20 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Brachyury protein, non-poxvirus non-yeast vectors encoding brachyury protein, and their use
AU2014265873B2 (en) 2013-03-19 2019-01-17 Globeimmune, Inc. Yeast-based immunotherapy for chordoma
TWI626948B (zh) 2013-03-26 2018-06-21 環球免疫公司 治療或預防人類免疫缺乏病毒感染之組合物及方法
US9725494B2 (en) * 2013-05-17 2017-08-08 United States Of America, As Represented By The Secretary, Department Of Health And Human Services Soluble CD27 (sCD27) and the use thereof
US10226522B2 (en) 2013-08-30 2019-03-12 Globeimmune, Inc. Compositions and methods for the treatment or prevention of tuberculosis
CA2948803A1 (en) * 2014-04-11 2015-10-15 Globeimmune, Inc. Yeast-based immunotherapy and type i interferon sensitivity
CN107406857B (zh) 2015-01-09 2021-06-29 埃图比克斯公司 用于联合免疫治疗的方法和组合物
US11149087B2 (en) 2015-04-20 2021-10-19 Etubics Corporation Methods and compositions for combination immunotherapy
AU2016303525B2 (en) * 2015-08-03 2021-01-21 Globeimmune, Inc. Modified yeast-Brachyury immunotherapeutic compositions
EP4137150A1 (en) * 2015-08-03 2023-02-22 The United States of America, as represented by the Secretary, Department of Health and Human Services Brachyury deletion mutants, non-yeast vectors encoding brachyury deletion mutants, and their use
KR20180117227A (ko) 2016-03-24 2018-10-26 난트셀, 인크. 네오에피토프 제시를 위한 시퀀스들 및 시퀀스 배열들
EP3463450A4 (en) * 2016-06-03 2020-07-29 Etubics Corporation COMPOSITIONS AND METHODS OF ANTI-TUMOR VACCINATION USING ANTIGENS ASSOCIATED WITH PROSTATE CANCER
WO2018094190A2 (en) * 2016-11-18 2018-05-24 Sanford Burnham Prebys Medical Discovery Institute Gut microbiota and treatment of cancer
US11779637B2 (en) 2017-04-24 2023-10-10 Nantcell, Inc. Targeted neoepitope vectors and methods therefor
KR20220068272A (ko) 2017-08-15 2022-05-25 난트셀, 인크. Hank 세툭시맙 조합 및 방법
CN119818663A (zh) 2018-05-15 2025-04-15 全球免疫公司 用于诱导细胞免疫应答的重组酵母裂解物
US11857620B2 (en) 2020-03-11 2024-01-02 Immunitybio, Inc. Method of inducing immunity against SARS-CoV-2 using spike (s) and nucleocapsid (N)-ETSD immunogens delivered by a replication-defective adenovirus
US12285480B2 (en) 2020-03-11 2025-04-29 Nantcell, Inc. Method of inducing immunity against SARS-CoV-2 using spike and nucleocapsid-ETSD immunogens delivered by RNA and replication-defective adenoviruses
US20210284716A1 (en) 2020-03-11 2021-09-16 Immunitybio, Inc. ACE2-Fc Trap
JP2024511277A (ja) 2021-02-19 2024-03-13 メビオン・メディカル・システムズ・インコーポレーテッド 粒子線治療システムのためのガントリー
EP4489774A4 (en) * 2022-03-08 2026-04-29 Immunitybio Inc YEAST-BASED VACCINE INJECTED INTRATUMORALLY

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1036329A (en) 1908-11-19 1912-08-20 Edison Inc Thomas A Phonograph-reproducer.
FR2486400B1 (fr) 1980-07-09 1986-05-30 Univablot Medicaments a base de levures ou de leurs extraits insolubles
NZ199722A (en) 1981-02-25 1985-12-13 Genentech Inc Dna transfer vector for expression of exogenous polypeptide in yeast;transformed yeast strain
US4775622A (en) 1982-03-08 1988-10-04 Genentech, Inc. Expression, processing and secretion of heterologous protein by yeast
US5310654A (en) 1985-07-31 1994-05-10 The Board Of Trustees Of The Leland Stanford Junior University Method for determining virulence of Yersinia
US5234830A (en) 1988-02-03 1993-08-10 Suntory Limited DNA encoding a KEX2 endoprotease without a C-terminal hydrophobic region
IL95019A0 (en) 1989-08-09 1991-06-10 Mycogen Corp Process for encapsulation of biologicals
US5413914A (en) 1993-07-07 1995-05-09 The Regents Of The University Of Colorado Yeast assay to identify inhibitors of dibasic amino acid processing endoproteases
US5830463A (en) 1993-07-07 1998-11-03 University Technology Corporation Yeast-based delivery vehicles
US5858378A (en) 1996-05-02 1999-01-12 Galagen, Inc. Pharmaceutical composition comprising cryptosporidium parvum oocysts antigen and whole cell candida species antigen
US20020044948A1 (en) 2000-03-15 2002-04-18 Samir Khleif Methods and compositions for co-stimulation of immunological responses to peptide antigens
AU1951001A (en) 2000-04-06 2001-09-17 Panacea Pharm Llc Microbial delivery system
AU2002225681A1 (en) 2000-11-15 2002-05-27 Globe Immune, Inc. Yeast-dentritic cell vaccines and uses thereof
KR101455222B1 (ko) 2002-12-16 2014-10-31 글로브이뮨 면역 요법으로서의 효모계 백신
US7439042B2 (en) 2002-12-16 2008-10-21 Globeimmune, Inc. Yeast-based therapeutic for chronic hepatitis C infection
SG163572A1 (en) * 2005-07-11 2010-08-30 Globeimmune Inc Compositions and methods for eliciting an immune response to escape mutants of targeted therapies
US20070172503A1 (en) 2005-12-13 2007-07-26 Mycologics,Inc. Compositions and Methods to Elicit Immune Responses Against Pathogenic Organisms Using Yeast Based Vaccines
US7736642B2 (en) * 2006-02-02 2010-06-15 Globeimmune, Inc. Yeast-based vaccine for inducing an immune response
BRPI0709340A2 (pt) 2006-03-27 2013-04-16 Globeimmune, Inc. mutaÇço ras e composiÇÕes e mÉtodos de uso da mesma
WO2008097863A2 (en) 2007-02-02 2008-08-14 Globeimmune, Inc. Methods for producing yeast-based vaccines
WO2008106551A2 (en) * 2007-02-28 2008-09-04 The Govt. Of The U.S.A. As Represented By The Secretary Of The Dept. Of Health & Human Serv. Brachyury polypeptides and methods for use
US8501167B2 (en) 2007-03-19 2013-08-06 Globeimmune, Inc. Compositions and methods for targeted ablation of mutational escape of targeted therapies for cancer
WO2009042645A2 (en) 2007-09-24 2009-04-02 President And Fellows Of Harvard College The use of mice predisposed to develop ulcerative colitis and colon cancer to develop metabolic profiles associated with same
WO2010033841A1 (en) 2008-09-19 2010-03-25 Globeimmune, Inc. Immunotherapy for chronic hepatitis c virus infection
WO2010065626A1 (en) 2008-12-02 2010-06-10 Globeimmune, Inc. Genotyping tools, methods and kits
MX2011010977A (es) * 2009-04-17 2012-02-29 Us Health Composiciones inmunoterapeuticas combinadas contra cancer y metodos.
CA2774326C (en) 2009-09-14 2023-11-07 Donald Bellgrau Modulation of yeast-based immunotherapy products and responses
EP2547792A4 (en) 2010-03-14 2013-11-27 Globeimmune Inc PHARMACOGENOMIC TREATMENT AND ADAPTATION TO THE RESPONSE OF AN INFECTIOUS DISEASE USING YEAST IMMUNOTHERAPY
WO2012019127A2 (en) * 2010-08-05 2012-02-09 The Regents Of The University Of Colorado Combination yeast-based immunotherapy and arginine therapy for the treatment of myeloid-derived supressor cell-associated diseases
US9254320B2 (en) 2010-12-17 2016-02-09 Globeimmune, Inc. Compositions and methods for the treatment or prevention of human adenovirus-36 infection
JP5745102B2 (ja) 2011-02-12 2015-07-08 グローブイミューン,インコーポレイテッド 慢性b型肝炎感染症のための酵母系免疫療法組成物
MX350661B (es) 2011-03-17 2017-09-13 Us Health Composiciones inmunoterapeuticas de levadura-brachyuri.
CN103732250A (zh) 2011-06-14 2014-04-16 全球免疫股份有限公司 基于酵母的治疗或预防丁型肝炎病毒感染的组合物和方法
SG10201607663YA (en) 2011-08-17 2016-11-29 Globeimmune Inc Yeast-muc1 immunotherapeutic compositions and uses thereof

Similar Documents

Publication Publication Date Title
JP2014509595A5 (2)
RU2013146324A (ru) Иммунотерапевтические композиции на основе дрожжей с brachyury
Zhang et al. Personalized cancer vaccines: Targeting the cancer mutanome
Vacchelli et al. Trial watch: Peptide vaccines in cancer therapy
JP2012524075A5 (2)
RU2014109741A (ru) Иммунотерапевтические композиции на основе дрожжей-muc1 и способы их применения
IL294183B2 (en) shared neoantigens
EP3545965A3 (en) Novel peptides and combination of peptides for use in immunotherapy against hepatocellular carcinoma (hcc) and other cancers
CN110621334A (zh) 个性化免疫原性肽鉴定平台
JP2018522041A5 (2)
Baratta Glioblastoma is ‘hot’for personalized vaccines
EP4357356A3 (en) Antigenic peptides for prevention and treatment of b-cell malignancy
JP2020511139A5 (2)
RU2019132253A (ru) Новая днк-вакцина, нацеленная на pd-l1, для иммунотерапии рака
Chen et al. The current therapeutic cancer vaccines landscape in non‐small cell lung cancer
Izzi et al. Poxvirus-based vaccines for cancer immunotherapy: New insights from combined cytokines/co-stimulatory molecules delivery and “uncommon” strains
Suzuki et al. Current status of vaccine immunotherapy for gastrointestinal cancers
JP2020507332A5 (2)
MX2020011787A (es) Nuevos peptidos y nueva combinacion de peptidos para el uso en la inmunoterapia contra el carcinoma hepatocelular (chc) y otros tipos de cancer.
Morse et al. Current immunotherapeutic strategies in colon cancer
Mohapatra et al. Cancer vaccines: types, mechanisms, and recent developments
Sasada et al. A patient with stage IV gastric cancer who acquired complete remission after undergoing multi-peptide dendritic cell immunotherapy in combination with standard therapies
Alanazi et al. Advances in Prostate Cancer Immunotherapy: Current Options and Emerging Novel Approaches
Dongbo et al. Can tumor vaccines really cure liver cancer?
Bhaliya et al. Current Strategies for the Development of a Therapeutic Cancer Vaccine–A Review